Treats acute lymphoblastic leukemia. ANDA 220225, held by Alembic. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 220225 (Methotrexate Sodium), held by Alembic, was first approved by FDA on Apr 15, 2026, with 0 approved supplements and 0 published complete response letters.
Methotrexate Injection is a folate analog metabolic inhibitor indicated for: The following neoplastic diseases for the: Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. Treatment of adult and pediatric patients with non-Hodgkin lymphoma. Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. Treatment of adults with breast cancer as part of a combination chemotherapy regimen. Treatment of adults with squamous cell carcinoma of the head and neck as a single agent.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 2026 | Original application | Approved | None posted |
| Methotrexate SodiumEQ 50MG BASE/2ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
| Methotrexate SodiumEQ 1GM BASE/40ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters